je.st
news
BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle
2015-11-30 16:10:16| Biotech - Topix.net
BioMarin's exon-skipping drug, drisapersen, has occupied biotechnology investors' minds over the past week. is a debilitating muscular disease that affects boys less than 10 years of age and slowly causes progressive muscle wasting resulting in loss of walking ability, and respiratory and cardiac failure with 100% death rate within few years.
Tags: panel
battle
biggest
fda
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||